<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355446</url>
  </required_header>
  <id_info>
    <org_study_id>0106-24</org_study_id>
    <nct_id>NCT00355446</nct_id>
  </id_info>
  <brief_title>Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.</brief_title>
  <official_title>Bioavailabilty of Bimatoprost Ophthalmic Solution in Human Aqueous.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assay human aqueous for bimatoprost and the presence of any&#xD;
      metabolites, especially prostaglandin analogs. Hypothesis:Bimatoprost is not metabolized to a&#xD;
      prostaglandin F-2-alpha analog in human eyes&#xD;
&#xD;
        -  Bimatoprost levels in human aqueous peak approximately three hours post dosing&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assay human aqueous for bimatoprost and the presence of any&#xD;
      metabolites, especially prostaglandin analogs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date>October 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bimatoprost free acid in human aqueous</measure>
  </primary_outcome>
  <enrollment>48</enrollment>
  <condition>Cataract</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost 0.03%</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects must:&#xD;
&#xD;
               1. Be willing and able to provide written Informed Consent.&#xD;
&#xD;
               2. Be able and willing to follow instructions and likely to complete the entire&#xD;
                  course of the study.&#xD;
&#xD;
               3. Be male or female of any race at least 18 years of age.&#xD;
&#xD;
               4. Have visually significant cataract for which they have elected to undergo&#xD;
                  cataract surgery..&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No subject may:&#xD;
&#xD;
             1. Have any contraindication to use of a prostaglandin analog or prostamide&#xD;
             derivative.&#xD;
&#xD;
             3. Have any active ocular disease other than glaucoma or ocular hypertension that&#xD;
             would interfere with study parameters (such as: uveitis, ocular infection, or severe&#xD;
             dry eye). Patients with mild chronic blepharitis, age-related macular degeneration,&#xD;
             background diabetic retinopathy may be enrolled at the discretion of the investigator.&#xD;
&#xD;
             4. Have laser or any other intraocular surgery within the past three months. 5.&#xD;
             Require use of ocular medications (including glaucoma medications), except&#xD;
             intermittent use of artificial tears. Patients may not have a history of ever having&#xD;
             used a prostaglandin analog topically.&#xD;
&#xD;
             6. Have known allergy or sensitivity to the study medications or their components 7.&#xD;
             Have corneal abnormalities that would interfere with the ability to obtain an adequate&#xD;
             sample safely or have a shallow anterior which would make obtaining an aqueous sample&#xD;
             difficult at the time of surgery in the opinion of the investigator.&#xD;
&#xD;
             8. Be concurrently enrolled in an investigational drug or device study or&#xD;
             participation within the last 30 days in any investigational drug or device study.&#xD;
&#xD;
             9. Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not&#xD;
             using a reliable form of contraception (a woman is considered of childbearing&#xD;
             potential unless she is postmenopausal, has had a uterus and/or both ovaries removed,&#xD;
             or has had a bilateral tubal ligation).&#xD;
&#xD;
             10. Have a situation or condition that in the investigator's opinion may put the&#xD;
             subject at significant risk, may confound the study results, or may interfere&#xD;
             significantly with participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis B Cantor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUPUI/Clarian</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wishard Memorial Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Eye at Carmel</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cantor LB, Donnenfeld E, Katz LJ, Gee WL, Finley CD, Lakhani VK, Hoop J, Flarty K. Penetration of ofloxacin and ciprofloxacin into the aqueous humor of eyes with functioning filtering blebs: a randomized trial. Arch Ophthalmol. 2001 Sep;119(9):1254-7.</citation>
    <PMID>11545629</PMID>
  </reference>
  <reference>
    <citation>Sjöquist B, Basu S, Byding P, Bergh K, Stjernschantz J. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos. 1998 Aug;26(8):745-54.</citation>
    <PMID>9698288</PMID>
  </reference>
  <reference>
    <citation>Basu S, Sjöquist B, Stjernschantz J, Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids. 1994 Apr;50(4):161-8.</citation>
    <PMID>8022849</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>July 20, 2006</study_first_submitted>
  <study_first_submitted_qc>July 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2006</study_first_posted>
  <last_update_submitted>October 16, 2007</last_update_submitted>
  <last_update_submitted_qc>October 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2007</last_update_posted>
  <keyword>Cataract</keyword>
  <keyword>Human Aqueous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

